- Home
- ELVA vs HURA Comparison
ELVA vs HURA Comparison
Compare ELVA & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVA
- HURA
- Stock Information
- Founded
- ELVA 1996
- HURA 2009
- Country
- ELVA Canada
- HURA United States
- Employees
- ELVA N/A
- HURA N/A
- Industry
- ELVA
- HURA
- Sector
- ELVA
- HURA
- Exchange
- ELVA Nasdaq
- HURA Nasdaq
- Market Cap
- ELVA 125.5M
- HURA 131.8M
- IPO Year
- ELVA N/A
- HURA N/A
- Fundamental
- Price
- ELVA $5.19
- HURA $2.45
- Analyst Decision
- ELVA Strong Buy
- HURA Strong Buy
- Analyst Count
- ELVA 3
- HURA 2
- Target Price
- ELVA $6.50
- HURA $11.50
- AVG Volume (30 Days)
- ELVA 578.4K
- HURA 176.3K
- Earning Date
- ELVA 12-11-2025
- HURA 11-14-2025
- Dividend Yield
- ELVA N/A
- HURA N/A
- EPS Growth
- ELVA 58.59
- HURA N/A
- EPS
- ELVA 0.03
- HURA N/A
- Revenue
- ELVA $54,875,000.00
- HURA N/A
- Revenue This Year
- ELVA $46.40
- HURA N/A
- Revenue Next Year
- ELVA $46.08
- HURA N/A
- P/E Ratio
- ELVA $192.08
- HURA N/A
- Revenue Growth
- ELVA 10.88
- HURA N/A
- 52 Week Low
- ELVA $1.73
- HURA $1.80
- 52 Week High
- ELVA $7.72
- HURA $7.20
- Technical
- Relative Strength Index (RSI)
- ELVA 34.15
- HURA 48.84
- Support Level
- ELVA $6.11
- HURA $2.40
- Resistance Level
- ELVA $6.72
- HURA $2.58
- Average True Range (ATR)
- ELVA 0.45
- HURA 0.11
- MACD
- ELVA -0.15
- HURA 0.02
- Stochastic Oscillator
- ELVA 2.26
- HURA 69.05
About ELVA Electrovaya Inc.
Electrovaya Inc designs develop and manufacture proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation and other specialized applications. It is a technology-focused company with extensive IP. The company generates revenue from the sale of batteries and battery systems. Business operations are segmented based on large format batteries and others. This technology offers enhanced safety and battery longevity. Geographically it earns key revenue from the United States.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.